Antitumour Immune Response and Cancer Vaccination: The Critical Role of Dendritic Cells

Summary Increasing the capacity of the immune system to mediate tumour regression has been a major goal in tumour immunology. Progress towards this goal has been recently aided by the identification of immunogenic cancer antigens and by a better understanding of the mechanisms of T-cell immune respo...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 1999, Vol.15 (4), p.321-326
Main Authors: Kochman, Serge, Bernard, Jacky
Format: Article
Language:English
Subjects:
Antigens, Neoplasm - immunology
Antineoplastic agents
Antitumoral immune response
Biological and medical sciences
Cancer immunotherapy
Cancer Vaccines - immunology
Dendritic cells
Dendritic Cells - immunology
Humans
Immune Tolerance - immunology
Immunotherapy
Medical sciences
Neoplasms - immunology
Neoplasms - prevention & control
Pharmacology. Drug treatments
T-Lymphocytes - immunology
Tumour antigen
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Increasing the capacity of the immune system to mediate tumour regression has been a major goal in tumour immunology. Progress towards this goal has been recently aided by the identification of immunogenic cancer antigens and by a better understanding of the mechanisms of T-cell immune response and tumour escape. A rare antigen-presenting cell -the dendritic cell (DC) - appears to be the key to these mechanisms. The passibilitgr of generating these cells in vitro from blood precursors has initiated a new era in cancer immunotherapy. Using DC as a cancer vaccine adjuvant has led to reports of measurable immune responses, and, in a few cases, to complete disease responses in patients with B-cell lymphoma and melanoma.
ISSN:0300-7995
1473-4877
DOI:10.1185/03007999909116504